Aberrant expression and potential therapeutic target of lysophosphatidic acid receptor 3 in triple-negative breast cancers
详细信息    查看全文
  • 作者:Kai Sun ; Hui Cai ; Xiaoyi Duan ; Ya Yang ; Min Li…
  • 关键词:Lysophosphatidic acid receptor ; Triple receptor ; negative breast cancer ; Aberrant expression ; Therapeutic target
  • 刊名:Clinical and Experimental Medicine
  • 出版年:2015
  • 出版时间:August 2015
  • 年:2015
  • 卷:15
  • 期:3
  • 页码:371-380
  • 全文大小:7,543 KB
  • 参考文献:1.Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-0. doi:10.-322/?caac.-0107 .PubMed View Article
    2.Poage GM, Hartman ZC, Brown PH. Revealing targeted therapeutic opportunities in triple-negative breast cancers: a new strategy. Cell Cycle. 2013;12(17):2705-. doi:10.-161/?cc.-5871 .PubMed Central PubMed View Article
    3.Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig. 2011;121(7):2750-7. doi:10.-172/?JCI45014 .PubMed Central PubMed View Article
    4.Speers C, Tsimelzon A, Sexton K, Herrick AM, Gutierrez C, Culhane A, et al. Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Clin Cancer Res. 2009;15(20):6327-0. doi:10.-158/-078-0432.?CCR-09-1107 .PubMed Central PubMed View Article
    5.Mohamed A, Krajewski K, Cakar B, Ma CX. Targeted therapy for breast cancer. Am J Pathol. 2013;183(4):1096-12. doi:10.-016/?j.?ajpath.-013.-7.-05 .PubMed View Article
    6.Gotoh M, Fujiwara Y, Yue J, Liu J, Lee S, Fells J, et al. Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis. Biochem Soc Trans. 2012;40(1):31-. doi:10.-042/?BST20110608 .PubMed Central PubMed View Article
    7.Willier S, Butt E, Grunewald TG. Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays. Biol Cell. 2013;105(8):317-3. doi:10.-111/?boc.-01300011 .PubMed View Article
    8.Kitayama J, Shida D, Sako A, Ishikawa M, Hama K, Aoki J, et al. Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma. Breast Cancer Res. 2004;6(6):R640-. doi:10.-186/?bcr935 .PubMed Central PubMed View Article
    9.Wu J, Mukherjee A, Lebman DA, Fang X. Lysophosphatidic acid-induced p21Waf1 expression mediates the cytostatic response of breast and ovarian cancer cells to TGFbeta. Mol Cancer Res. 2011;9(11):1562-0. doi:10.-158/-541-7786.?MCR-11-0340 .PubMed Central PubMed View Article
    10.Hama K, Aoki J, Fukaya M, Kishi Y, Sakai T, Suzuki R, et al. Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J Biol Chem. 2004;279(17):17634-. doi:10.-074/?jbc.?M313927200 .PubMed View Article
    11.David M, Ribeiro J, Descotes F, Serre CM, Barbier M, Murone M, et al. Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis. Int J Oncol. 2012;40(4):1133-1. doi:10.-892/?ijo.-011.-309 .PubMed Central PubMed
    12.Boucharaba A, Serre CM, Guglielmi J, Bordet JC, Clezardin P, Peyruchaud O. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci USA. 2006;103(25):9643-. doi:10.-073/?pnas.-600979103 .PubMed Central PubMed View Article
    13.Samadi N, Bekele RT, Goping IS, Schang LM, Brindley DN. Lysophosphatidate induces chemo-resistance by releasing breast cancer cells from taxol-induced mitotic arrest. PLoS One. 2011;6(5):e20608. doi:10.-371/?journal.?pone.-020608 .PubMed Central PubMed View Article
    14.Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F, et al. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell. 2009;15(6):539-0. doi:10.-016/?j.?ccr.-009.-3.-27 .PubMed Central PubMed View Article
    15.Popnikolov NK, Dalwadi BH, Thomas JD, Johannes GJ, Imagawa WT. Association of autotaxin and lysophosphatidic acid receptor 3 with aggressiveness of human breast carcinoma. Tumour Biol. 2012;33(6):2237-3. doi:10.-007/?s13277-012-0485-1 .PubMed View Article
    16.Sengupta S, Xiao YJ, Xu Y. A novel laminin-induced LPA autocrine loop in the migration of ovarian cancer cells. FASEB J. 2003;17(11):1570-. doi:10.-096/?fj.-2-1145fje .PubMed
    17.Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869-4. doi:10.-073/?pnas.-91367098 .PubMed Central PubMed View Article
    18.Panupinthu N, Lee HY, Mills GB. Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression. Br J Cancer. 2010;102(6):941-. doi:10.-038/?sj.?bjc.-605588 .PubMed Central PubMed View Article
    19.Witt AE, Hines LM, Collins NL, Hu YH, Gunawardane RN, Moreira D, et al. Functional proteomics approach to investigate the biological activities of cDNAs implicated in breast cancer. J Proteome Res. 2006;5(3):599-10. doi:10.-021/?Pr050395i .PubMed Central PubMed View Article
    20.Goetzl
  • 作者单位:Kai Sun (1)
    Hui Cai (2)
    Xiaoyi Duan (3)
    Ya Yang (1)
    Min Li (1)
    Jingkun Qu (1)
    Xu Zhang (4)
    Jiansheng Wang (1)

    1. The Second Department of Thoracic Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, 277 West Yanta Road, Xi’an, 710061, Shaanxi, China
    2. Department of Anesthesia, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China
    3. Department of Nuclear Medicine, The First Affiliated Hospital of Xi’an Jiaotong University, 277 West Yanta Road, Xi’an, 710061, Shaanxi, China
    4. Department of Pathology, Lanzhou University Medical School, Lanzhou, Gansu, China
  • 刊物主题:Internal Medicine; Hematology; Oncology;
  • 出版者:Springer Milan
  • ISSN:1591-9528
文摘
Triple receptor-negative breast cancers (TNBCs) generally have poor prognoses because of the loss of therapeutic targets. As lysophosphatidic acid (LPA) receptor signaling has been shown to affect breast cancer initiation and progression, we try to evaluate the potential roles of LPA receptors in TNBCs. We examined mRNA and protein expressions of LPA receptors 1-3, using quantitative real-time PCR and immunohistochemical analyses in normal (n?=?37), benign disease (n?=?55), and breast cancer tissues (n?=?82). Carcinomas expressed higher levels of LPA2 and LPA3 mRNAs (0.17?±?0.070 and 0.05?±?0.023, respectively) than did normal breast tissue (0.13?±?0.072 and 0.02?±?0.002, respectively). Enhanced immunohistochemical staining for LPA2 and LPA3 protein was also consistently observed in carcinomas. The LPA3 overexpression was associated with lymph node metastases, and absence of estrogen receptor, progesterone receptors, and human epidermal growth factor receptor 2 expression. TNBC tissues and cell lines showed the highest LPA3 expression compared with luminal-type A and B breast cancers. Suppression of LPA3 by shRNA did not influence cell growth in breast cancer cells. However, the migration and invasion of TNBC cells were significantly inhibited by LPA3-shRNA or inhibitor, which had no or less effect on normal and non-TNBC breast cells. In conclusion, our data indicated that the expression of LPA receptor 3 was increased in human TNBCs and is associated with tumor metastatic ability, and this implies that LPA3 is a potential therapeutic target for the treatment of TNBCs.

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址:北京市海淀区学院路29号 邮编:100083

电话:办公室:(+86 10)66554848;文献借阅、咨询服务、科技查新:66554700